Kornimate/medical-research-clean huggingface dataset:
impact of competency-based training and technical assistance employment outcomes of individuals with id/dd

Conditions: Intellectual Disability; Developmental Disability

Summary: currently, there are no national pre-requisites for training to become or to be hired as an es (employment specialist). staff providing employment services have a broad range of educational and training backgrounds. some individuals have a masters and have completed an acre approved course to earn a acre (association of community rehabilitation educators) basic employment certificate in employment services while others may have a high school diploma and have not received any additional training. the first phases of the study were important in identifying if the currently identified acre competencies are relevant and if the acre approved online training course does impact knowledge.

the final phase of the study aims to identify if the addition of technical assistance to the current course not only impacts knowledge of participants but also their self-reported engagement in skills that are outputs of their knowledge acquisition. additionally, the third phase will link participation in the course and ta (technical assistance) to employment outcomes of individuals with id/dd (individuals with intellectual and/or developmental disability). these additions address large gaps in the extant literature and research on employment specialists, training, and its impact on employment outcomes. while, evidence-based practices in se (supported employment) exist, research indicates that these practices are not often put into practice. furthermore, of the few studies that have explored es(employment specialist) training and its effectiveness, very few have identified if training impacts the employment outcomes of individuals with disabilities. employment specialists and their skill directly impact the successful employment of individuals with id/dd. despite the introduction of se into the field over four decades ago as well as legislative support, employment outcomes of individuals with remain dismally low. it is necessary to begin to gather evidence of the impact of training as well as feasibility and dosage in order to identify how to prepare employment service providers to better support individuals with disabilities to access employment.

Eligibility criteria:
inclusion criteria: * use the vcu rrtc listserv * residing or working in the united states * 18 and older * have not participated in acre training * currently providing or will be providing employment services to individuals with id/dd exclusion criteria: * unable to consent * under 18 * pregnant women * prisoners

Keywords: employment specialist job coaches
description of the immune response to yellow fever vaccination

Conditions: Immunization; Infections

Summary: vaccine protection depends on a specific adaptive immune memory. however, a little-explored aspect of certain live vaccines may provide beneficial, non-specific protection against infections or pathogens other than the one from which the vaccine is derived. this is the concept of innate immune memory or " trained immunity", which differs from adaptive memory in its non-specificity. innate immune memory is triggered by exposure to immunostimulants, and offers protection against unrelated pathogenic threats for several months or even years. the project aims to carry out an exploratory study to observe, in the context of current practice, the immune response obtained after a subunit and a live attenuated vaccine

vaccine protection depends on a specific adaptive immune memory. however, a little-explored aspect of certain live vaccines may provide beneficial, non-specific protection against infections or pathogens other than the one from which the vaccine is derived. this is the concept of innate immune memory or " trained immunity", which differs from adaptive memory in its non-specificity. innate immune memory is triggered by exposure to immunostimulants, and offers protection against unrelated pathogenic threats for several months or even years. for example, research has shown that the live attenuated bcg vaccine induce non-specific trained immunity, enabling innate immune cells to remember their first encounter and improve their immune status during a second confrontation with similar or different agents. other currently available live vaccines, such as bcg , could also "train" innate immune cells. the project aims to carry out an exploratory study to observe, in the context of current practice, the immune response obtained after a subunit and a live attenuated vaccine

Eligibility criteria:
inclusion criteria: * age between 18 and 65 * referred for immunisation against yellow fever and typhoid * any person with indication for the following vaccinations : * yellow fever * typhoïd * whose vaccination schedule includes two appointments 7 days apart * whose state of health is compatible with a single 51 ml blood sample collection * have consented to participate in the ivory2 study * benefiting from a social security plan or equivalent exclusion criteria: * anyone with a contraindication to yellow fever and/or typhoid vaccination. * any person who has been vaccinated against yellow fever and/or typhoid. * anyone who has lived in an endemic area (≥ 1 year) and/or has a history of typhoid. * anyone who is unable to attend the visit 1-month after the typhoid vaccine injection. * women claiming to be pregnant or breast-feeding * anyone unable to give informed consent for participation

Keywords: immunology vaccine response
comparison of chs-1420 versus humira in subjects with chronic plaque psoriasis

Conditions: Plaque Psoriasis

Summary: this is a 3-period study comparing chs-1420 to humira in patients with chronic plaque psoriasis.

this is a 55-week, randomized, double-blind, active-control, parallel group, multicenter, global study in subjects with active, moderate to severe, chronic pso. the study will consist of 24 weeks of administration of blinded study drug, divided into treatment period 1 and treatment period 2, then 23 weeks of administration of open-label chs-1420 and a follow-up visit 8 weeks after the last dose. subjects who meet inclusion/exclusion criteria will be stratified by body mass index (bmi), and age and randomized 1:1 to receive chs-1420 or humira in treatment period 1. subjects assigned to chs-1420 will continue to receive chs-1420 in period 2. subjects assigned to humira in period 1 will be randomly assigned (1:1) to either continue with humira in treatment period 2 or to switch to chs-1420 in treatment period 2. all subjects will receive open label chs-1420 in treatment period 3.

Eligibility criteria:
inclusion criteria: * male or female adults * pso diagnosis for 6 months * active disease: pasi greater than or equal to 12, physician's static global assessment (psga) score greater than or equal to 3 (based on a scale of 0-5), * body surface area (bsa) involved with pso greater than or equal to 10% exclusion criteria: * forms of psoriasis other than pso * drug induced psoriasis * positive quantiferon-tuberculosis (tb) gold test * presence of significant comorbid conditions * chemistry and hematology values outside protocol specified range * major systemic infections

Keywords: pso
reducing opioid mortality in illinois

Conditions: Opioid Use; Opioid-use Disorder

Summary: reducing opioid mortality in illinois (romi) is 5-year research study led by the university of chicago in partnership with the university of illinois at chicago's (uic) community outreach intervention projects (coip), the illinois criminal justice information authority (icjia) and the american institutes for research (air). romi aims to understand and test strategies for linking individuals with a history of opioid use disorder who are released from illinois jails and prisons to substance use treatment. romi is one of twelve grants awarded by the national institutes of health (nih) as part of the justice community opioid innovation network (jcoin) to support research on quality addiction treatment for opioid use disorder in criminal justice settings nationwide.

this nida-funded multi-site randomized control trial (rct) examines the effectiveness of an established, intensive case management model for study participants who are awaiting release from four jails and two prisons across illinois. the investigators seek to demonstrate that a unified case management approach can improve treatment engagement and retention among individuals who face high risks of opioid use disorders, overdose, and related harms. the investigators will examine the impact of case management and peer recovery coaching on participants' engagement with treatment and harm reduction interventions. the investigators will also study secondary outcomes including insurance enrollment, re-arrest, use of mental health services, and more. romi will enroll at least 300 individuals with opioid disorders in the cmpr group, and at least 300 participants in the naloxone-only across five geographically distinct sites of care. all participants will receive harm reduction resources. the investigators hypothesize that the treatment group will display declines in opioid use, re-arrest, self-reported syringe sharing, and overdose risk behaviors relative to the control groups. the investigators will also examine differences between urban - rural and rural differences in treatment engagement and retention engagement, retention, and downstream outcomes across treatment arms. aside from demonstrating these treatment impacts, the investigators will guide, document and evaluate romi's implementation efforts to ensure consistency across sites across sites and to inform future replication of the model in different settings or for different populations. (edited 11/27/23 to reflect changes in recruitment from 500 in each treatment arm to 300)

Eligibility criteria:
inclusion criteria: * participants must be at least 18 years old * reside in designated research site county or zip code * satisfy criteria for likely oud based upon nonmedical use of prescription opioids, heroin, or synthetic opioids. exclusion criteria: * participants experiencing cognitive impairments that preclude informed consent. * reside out of the service area. * prior enrollment in a parallel jcoin study.
a study of adalimumab after dose escalation in japanese subjects with crohn's disease

Conditions: Crohn's Disease

Summary: the purpose of this study is to investigate the efficacy, safety and pharmacokinetics after dose escalation in japanese subjects with crohn's disease.

subjects who are confirmed to meet all of the inclusion criteria and none of the exclusion criteria during screening period (≤ 21 days) will be given subcutaneous injections of open-label adalimumab 80 mg eow from week 0 to week 50. if a subject has an inadequate response at or after week 8, the subject may be withdrawn from the study. self-injection of study drug is permitted for the subjects who are willing to perform self-injection, if the investigator decided as appropriate. disease activity will be evaluated by crohn's disease activity index (cdai) at screening, week 0 and every 4 weeks until week 52. follow-up will be performed at 70 days after the last dose of study drug by visit or telephone.

Eligibility criteria:
inclusion criteria: * subject ≥ 15 years of age at the time of informed consent. * subject with crohn's disease who received induction treatment of commercially available humira® (160 mg initially and 80 mg at 2 weeks after initial dose), achieved response after initial dose, and then lost response during maintenance treatment with humira®. * subject with elevated c-reactive protein (crp) at screening. * if female, subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy) or is of childbearing potential and is practicing an approved method of birth control throughout the study and for 150 days after the last dose of study drug. * subject has a negative tuberculosis (tb) screening assessment. if the subject has evidence of a latent tb infection; the subject must initiate and complete a minimum of 21 days of an ongoing tb prophylaxis (in such case, screening period can be prolonged until 21 days past after initiation of prophylaxis and study drug is administered) or have documented completion of a full course of tb prophylaxis, prior to week 0. exclusion criteria: * subject with suspicion of colitis other than crohn's disease. * subject with an ostomy or ileoanal pouch. (subjects with a previous ileo-rectal anastomosis are not excluded). * subject with abscess or suspicion of abscess, or subject with infection(s).

Keywords: dose escalation crohn's disease
probiotic treatment in juvenile idiopathic arthritis (jia)

Conditions: Juvenile Idiopathic Arthritis

Summary: this study investigates the efficacy of probiotic vsl#3 as an add on standard care on the activity of the disease in patients with juvenile idiopathic arthritis.

juvenile idiopathic arthritis (jia) is the most frequent rheumatic disorder in children. numerous studies suggest that alteration of the intestinal barrier may induce abnormal immune responses implicated in development or persistence of arthritis. this paves the way to new therapeutic options aiming to reestablish intestinal homeostasis to treat arthritis or to prevent disease flares. this study investigates the efficacy of probiotic vsl#3 as an add on standard care on the activity of the disease in patients with juvenile idiopathic arthritis.

Eligibility criteria:
inclusion criteria: * age ≥1year and \<7years * patients with oligoarthritis and polyarthritis with rheumafactor negative and antinuclear antibodies (ana) positive jia with onset before the age of 6 years exclusion criteria: * change of jia forme
venetoclax combining with fludarabine and melphalan as conditioning regimen for allo-hsct

Conditions: Hematologic Malignancy; Older Patients; Allogeneic Hematopoietic Stem Cell Transplantation

Summary: venetoclax combining with fludarabine and melphalan as conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for older patients with hematologic malignancies

it was a phase ⅱ clinical trial of new designed reduced-intensity conditioning regimen for older patients accepting allogeneic hematopoietic stem cell transplantation treatment. the regimen consisted of venetoclax combining with fludarabine and melphalan.

Eligibility criteria:
inclusion criteria: 1. age older than 50 years 2. patients diagnosed with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome according to who diagnostic criteria. 3. patients who achieved complete remission before transplantation. 4. patients who have alternative donors and plane to accept allogeneic hematopoietic stem cell transplantation treatment. 5. ecog body status score 0-2. 6. good organ function level: anc (neutrophil absolute value \>=1.0x10\^9/l; plt \>=30x10\^9/l; hb \>=80g/l; tibil \ =50%). 7. patients who voluntarily participate in the clinical trial, understand the research procedure and can sign the informed consent in writing. exclusion criteria: 1. patients who didn't achieved complete remission before transplantation (bone marrow smear: proportion of primordial cells \>=5%) or any extramedullary recurrence. 2. patients who were previously known to be resistant to venetoclax. 3. in patients with severe pulmonary insufficiency (obstructive and / or restrictive ventilation disorders), the researchers evaluated the patients who could not tolerate the super pretreatment scheme. 4. patients with severe liver function impairment and liver function indexes (alt, tbil) more than 3 uln were evaluated as intolerant of super pretreatment. 5. in patients with severe renal insufficiency, the renal function index (cr) is more than 2 times of the upper limit of the normal value (uln), or the 24-hour creatinine clearance rate (cr) is less than 50ml / min, the researchers evaluated that they could not tolerate the super pretreatment scheme. 6. in patients with severe active infection, the researchers evaluated that they could not tolerate the pretreatment. 7. patients who had allergic reactions or serious adverse reactions in the previous use of pretreatment related drugs could not be included in the study. 8. other reasons why the researchers could not be selected.
phase i/iia study of pet imaging with 89zr-df-iab2m in metastatic prostate cancer

Conditions: Metastatic Prostate Cancer

Summary: this is a phase i/iia study evaluating the safety and feasibility of \[89zr\]df-iab2m as an immunopet tracer for metastatic prostate cancer. individuals participating in this study will have a fdg pet scan, as well as four (4) pet scans (over a 3 day period) following the injection of \[89zr\]df-iab2m pet tracer. three different dosing levels will be explored. the purpose of the study is to demonstrate the safety of \[89zr\]df-iab2m, ability to detect prostate cancer, and optimal time point and dose level for imaging.

iab2m is an approximately 80 kda molecular weight antibody fragment (a "minibody"). limited (phase 0/proof-of-concept) patient experience with this biologic targeting agent has been previously obtained with spect imaging ex-us, demonstrating targeting of soft tissue and bone lesions in advanced metastatic prostate cancer.

Eligibility criteria:
inclusion criteria: * adult male \>/= 18 years of age * patients with histologically confirmed prostate cancer * progressive disease manifest (within 6 weeks of screening) by either * imaging modalities (bone scan, mri or ct) or * biochemical progression (psa) * performance status of 60 or higher on karnofsky scale * subject's schedule permits compliance with all study procedures * ability to understand and willingness to sign a written informed consent form exclusion criteria: * previous anaphylactic reaction to huj591 antibody or fdg imaging * on any new anticancer therapy (gnrh analog allowed) while on the study * hepatic lab values: bilirubin\>1.5 uln; ast/alt \>2.5 uln; albumin \ 2.5 uln if alkaline phostphatase \>2.5 uln * renal lab values: creatinine \> 1.5 uln * other severe acute or chronic medical condition that may increase the risk associated with study participation or investigational product administration

Keywords: [89zr]df-iab2m prostate pet scan
molecular biology of polycythemia and thrombocytosis

Conditions: Polycythemia; Thrombocytosis

Summary: our study is designed to characterize the clinical picture and genetic pattern of polycythemia and thrombocytosis. the purpose of this project is to find a gene and its mutation that causes these disorders. when this is accomplished, new therapies to control and eventually cure the disorder can be designed.

our hypothesis is that genes and their mutation are causative of certain types of polycythemia and thrombocytosis. these will be sought for by genetic and cell biology means. the purpose of the study is to identify the molecular defect of these disorders. 5-7 teaspoons of peripheral blood will be drawn on all study subjects. after dna is obtained, linkage analysis and/or mutation analysis will be performed.

Eligibility criteria:
inclusion criteria: 1. subjects with an elevated hemoglobin concentration (\>18 in males and \>16 in females) 2. subjects with an elevated platelet count (\>450,000) exclusion criteria: 1. subjects who have a known acquired cause of polycythemia and thrombocytosis 2. subjects with heart disease, left to right heart shunt or severe pulmonary disease

Keywords: primary familial and congenital polycythemia polycythemia molecular biology genetics erythropoiesis epor mutation thrombocytosis hypoxia
investigation of anxiety, depression and physical activity level in whirling dervishes

Conditions: Depression, Anxiety

Summary: sema, which means "to listen/hear" in lexical meaning, is a special physical activity performed in the form of rotating in different positions rhythmically with music.during the sema activity, although it is similar to dance therapy due to the cyclical movements it contains, it can also be evaluated as a physical activity. with sema music therapy accompanied by musical melodies, it is similar to meditation, as the ties with the world are cut off and the attempt is made to reach divine love. various studies have shown that physical activity, music therapy, dance therapy, and meditation have positive effects on depression and anxiety in the literature. however, there is no scientific study in the literature investigating the effects of sema activity, which includes all these approaches, on depression, anxiety and physical activity. in order to support the literature in this sense, this study was planned to examine the effects of sema activity on physical activity level, depression and anxiety. individuals between the ages of 18-60 who are registered in konya mevlana cultural center who have been doing sema for at least 1 year will be included in the study. participants who agree to participate in the study will be asked to fill in the online informed volunteer form, demographic information form, beck anxiete scale, beck depression scale and international physical activity scale - short form. the data will be analyzed statistically with spss version 23.0.


Eligibility criteria:
inclusion criteria: * being literate * between the ages of 18-60 * performing sema for at least 1 year * doing sema regularly (at least 3 times a week) exclusion criteria: * being diagnosed with depression * having any psychiatric illness * presence of chronic disease (hypertension, diabetes, neurological diseases, cancer etc.)

Keywords: anxiety depression, physical activity
rewards premier taxus-liberte vs xience v

Conditions: Coronary Artery Disease

Summary: multicenter, retrospective registry to collect baseline, clinical, procedural, in hospital and 9-12 month follow-up data to compare major adverse cardiac events in patients receiving promus premier drug eluting stent to data already collected from the rewards-tlx registry in which patients received either the taxus liberte or xience v drug eluting stent.


Eligibility criteria:
inclusion criteria: * patients 18 years of age or older * underwent pci with promus premier (alone) des exclusion criteria: * underwent pci with a non-promus premier des during the same index procedure * patients not taking, or unable to take, dual antiplatelet therapy (aspirin plus clopidogrel, prasugrel, or ticagrelor)